Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

the treatment of cancer.  VAL-083 has been assessed in multiple clinical studies sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.

DelMar is currently conducting a Phase I/II clinical trial with VAL-083 as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  In April 2012, DelMar presented data at the American Association of Cancer Research (AACR website:  http://www.aacr.org) annual meeting demonstrating that VAL-083 maintains activity in tumors resistant to the current front-line GBM therapy, Temodar®.  In November 2012, DelMar presented interim data from the ongoing GBM clinical trial at the Annual Meeting of the Society for NeuroOncology (SNO website:  http://www.soc-neuro-onc.org) demonstrating that VAL-083 can shrink or halt the growth of tumors in brain cancer patients who have failed other approved treatments.  Currently, there is no approved therapy for these patients. 

In addition to the Company's clinical development activities in the United States, DelMar has obtained exclusive commercial rights to VAL-083 in China.  In October 2012, DelMar announced a collaboration agreement with the only manufacturer presently licensed by the Chinese State Food and Drug Administration (SFDA) to produce VAL-083 for the China market.  This agreement provides DelMar with exclusive commercial right
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Alliance ... a multi-stakeholder non-profit collaborative building a global system ... research, today announced Phase 3 of its Site ... , Amir H. Kalali, Vice-President, Global Head, Neuroscience ... President, Compliance and Quality Integration (CQI) Consulting will ...
(Date:9/16/2014)... can harvest energy from jaw movements has been created ... is hoped that the device can generate electricity from ... small-scale implantable or wearable electronic devices, such as hearing ... , The first results of the device,s performance have ... Smart Materials and Structures . , Jaw movements ...
(Date:9/16/2014)... to cars and flashlights, batteries play an important ... constantly are seeking ways to improve battery life ... a water-based solution, researchers at the University of ... nuclear battery that could be used for many ... automobiles and also in complicated applications such as ...
(Date:9/16/2014)... Sept. 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... has been shown to be effective in animal models ... alternative to intravenous infusions that could pave the way ... were presented yesterday at the Heart Failure Society of ... Las Vegas . The ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... Popular Emergency Department Information, System Also Includes Embedded Web ... ... DALLAS, Oct. 24 T-System, Inc., the leading provider of,clinical ... announced the release of The T SystemEV(R),2.6.3, the newest upgrade to ...
... JERUSALEM, October 24 IDenta Corp. (Other,OTC: IDTA.PK) ... penetration of the United States and Oversees markets., ... Corporation (Encino,CA) and IDenta Corporation continues, has resulted ... quarters of 2008. Accutest(R) IDenta sales,have increased significantly ...
... held October 29-31 at the Palace Hotel, San,Francisco, ... Group, the world,s,marketplace for expertise, and the Biotechnology ... the Seventh Annual BIO Investor,Forum. Featured therapeutic panels ... consultants along with executives from public and,private equity ...
Cached Biology Technology:T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 2T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 2Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 3
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] After decades of decline, ... Cod,s saltmarshes. To the eye, the marsh in those ... clear that a key service of the marsh ... aesthetics back but the ecosystem function hasn,t come back," ... and senior author of the study in the journal ...
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... cell factor overexpressed both in brain tumor cells and ... inducing angiogenesis. The research study, published in the April ... cells and surrounding tissues and may have substantial significance ... the most lethal types of tumor, malignant gliomas. ...
... play an important role in regulating blood flow in ... assumptions underlying today's most sophisticated brain imaging techniques and ... understanding Alzheimer's disease. , In a paper to appear ... available on-line, scientists at the University of Rochester Medical ...
... the Virginia Bioinformatics Institute at Virginia Tech have ... range of microbial genome sequences. , The VBI ... recent article published in Nucleic Acids Research (Vol.34, ... the plant pathogens Phytophthora sojae and Phytophthora ramorum. ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Blood flow in brain takes a twist, affecting views of Alzheimer's 2Blood flow in brain takes a twist, affecting views of Alzheimer's 3Virginia Bioinformatics Institutes launches microbial database 2